Patent intelligence · US
US 11208405
Pyrrole derivatives as PLK1 inhibitors
Pyrrole derivatives as PLK1 inhibitors
Patent details — US 11208405
- Jurisdiction
- US
- Status
- granted
- Grant date
- Dec 28, 2021
- Expiration
- Dec 23, 2041
- Applicant
- SENTINEL ONCOLOGY LIMITED
- Claims
- 17
- CPC classes
- A61P, A61P35/00
Quick answer
US 11208405 (Pyrrole derivatives as PLK1 inhibitors) is held by SENTINEL ONCOLOGY LIMITED. Status: granted. Granted Dec 28, 2021. Expires Dec 23, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- SENTINEL ONCOLOGY LIMITED
- Grant date
- Expiration
- Claims
- 17
- CPC classes
- A61P, A61P35/00
More from SENTINEL ONCOLOGY LIMITED
Related pharmaceutical patents in our USPTO index.
-
US 12419895
Methods for treating subjects with Prader-Willi syndrome
granted -
US 12350258
Compositions and methods for treatment of skin-related diseases and promoting dermatological health
granted -
US 12343348
Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome
granted -
US 12343381
Dosage regimen for pegylated interferon
granted -
US 12178823
Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome
granted -
US 12109216
Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome
granted -
US 12005081
Chimeric receptors and methods of use thereof
granted -
US 11884656
Pyrrole derivatives as PLK1 inhibitors
granted
Frequently asked questions
What is US patent 11208405?
US 11208405 (Pyrrole derivatives as PLK1 inhibitors) is held by SENTINEL ONCOLOGY LIMITED. Status: granted. Granted Dec 28, 2021. Expires Dec 23, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11208405?
SENTINEL ONCOLOGY LIMITED is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 95 pharmaceutical patents for this assignee.
When does US 11208405 expire?
Our index shows an expiration date of Dec 23, 2041 (15 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.